| Index | Recent Threads | Unanswered Threads | Who's Active | Guidelines | Search |
 |
World Community Grid Forums
Category: Active Research
Forum: Mapping Cancer Markers Forum
Thread: Interesting News Articles About Cancer |
| No member browsing this thread |
|
Thread Status: Active Total posts in this thread: 530
|
|
| Author |
|
|
l_mckeon
Senior Cruncher Joined: Oct 20, 2007 Post Count: 439 Status: Offline Project Badges: 
|
Breakthrough discovery of signal cancers use to hide from immune system
Cancer cells often deploy specific "don't eat me" signals to hide from immune cells. A breakthrough new study from Stanford University has homed in on a previously undiscovered signaling protein that, if effectively inhibited, may lead to new treatments for breast, ovarian, and other difficult-to-treat cancers. CD47 is a recently discovered signaling protein currently being investigated in a number of different human clinical trials. CD24, a signaling protein not dissimilar to CD47, appeared in high volumes on the surface of cancer cells being ignored by the [immune system] macrophages. "Finding that not all patients responded to anti-CD47 antibodies helped fuel our research at Stanford to test whether non-responder cells and patients might have alternative 'don't eat me' signals," says Irving Weissman, senior author on the new study. This means cancers that didn't respond effectively to CD47 blocking did respond well to CD24 blocking, and vice versa. Ovarian and triple-negative breast cancer were specifically noted as responding well to the new CD24-blocking method. Much more at: https://newatlas.com/stanford-immunotherapy-cd24-cancer-signal-protein/60856/ |
||
|
|
l_mckeon
Senior Cruncher Joined: Oct 20, 2007 Post Count: 439 Status: Offline Project Badges:
|
Scientists pluck an anti-cancer compound from a common flower
The compound in question is called parthenolide, and it's been under this kind of investigation for years. Scientists have suspected that the compound is an anti-cancer agent, but it's been hard and expensive to make in useful amounts. Feverfew and related plants are high in parthenolide, so the Birmingham team started by figuring out the best candidate for extracting the compound. [Feverfew itself, late in flowering] The [modified variant, one of 76 attempts] was put to work fighting a form of cancer called chronic lymphocytic leukemia (CLL), and in tests on cultured cancer cells, it appeared to be effective. The compound works by raising the levels of reactive oxygen species (ROS), unstable molecules that can be toxic to cells. ROS are also being investigated as potential antibacterial agents, and since levels are already higher in cancer tissue than healthy cells, the compound helps push it over the edge. Human tests are likely to follow. More at: https://newatlas.com/anti-cancer-compound-common-flower-feverfew/60872/ |
||
|
|
Jim Slade
Veteran Cruncher Joined: Apr 27, 2007 Post Count: 664 Status: Offline Project Badges:
|
The Human Genomic Revolution: Past, Present, and Future (2019)
Over 15 years ago the scientific community celebrated the sequencing of the first human genome. It's time to ask how this monumental effort has transformed biomedical science, from basic research to the understanding and treatment of disease. Eric Lander, Broad Institute president and founding director and one of the principal leaders of the Human Genome Project, will survey the impact-and what we've learned, and what lies ahead. https://www.broadinstitute.org/videos/human-g...n-past-present-and-future  |
||
|
|
l_mckeon
Senior Cruncher Joined: Oct 20, 2007 Post Count: 439 Status: Offline Project Badges:
|
Scientists demonstrate a new nano-vaccine preventing the spread of melanoma, in mice.
A new nano-vaccine is showing promising results in treating skin cancer in mouse models. Developed by scientists at Tel Aviv University, the prospective vaccine encases two experimental new cancer drugs inside a tiny nanoparticle, with initial experiments revealing the therapy can both stimulate the immune system to kill melanoma, and act as a preventative vaccine stopping the cancer from developing in the first place. The new research describes the development of tiny nanoparticles that are filled with a combination of two novel experimental cancer drugs, an anti-PD1 antibody and an anti-OX40 antibody. Both molecules are designed to stimulate the body's immune system to attack tumor cells and are encased in tiny biodegradable polymers called mannosylated nanoparticles. More at: https://newatlas.com/nanoparticle-cancer-vaccine-melanoma-skin-cancer/60913/ |
||
|
|
l_mckeon
Senior Cruncher Joined: Oct 20, 2007 Post Count: 439 Status: Offline Project Badges:
|
Slow-and-steady drug combo wins race against pancreatic cancer [in mice]
Pancreatic cancer is one of the most deadly forms of the disease, thanks largely to the fact that the tumors tend to be much more solid. This means that cancer drugs aren't able to get inside to work their magic. But now researchers have identified a promising new drug candidate that could linger for longer to worm its way in, and it works especially well when paired with other cancer drugs. A promising candidate was an experimental compound called PTC596, which has previously shown promise against pancreatic cancer in mice and cultured human cells. The drug has been found to stick around for much longer than others and to top it all off, it can even avoid a natural "pump" that cancer cells use to reject substances like drugs. To test PTC596, the team combined it with another drug called gemcitabine, which is currently used as a first-line drug against pancreatic cancer. Better yet, the researchers then added a third drug to the mix and things improved even further. Known as nab-paclitaxel, this drug is also commonly used to treat pancreatic cancer and when combined with PTC596 and gemcitabine, the trio worked to shrink tumors. [in mice] More at: https://newatlas.com/slow-drug-combo-pancreatic-cancer/61007/ |
||
|
|
Jim Slade
Veteran Cruncher Joined: Apr 27, 2007 Post Count: 664 Status: Offline Project Badges:
|
Cancer Patients Have Limited Understanding of Genomic Test Results
A significant portion of patients with cancer don't understand the potential uses for their genomic test results A majority of patients with cancer don't understand critical features of the genomic test results they receive when participating in clinical trials, according to a pilot study conducted under the Lung Cancer Master Protocol (Lung-MAP), the first lung cancer precision medicine trial supported by the National Cancer Institute (NCI). https://healthitanalytics.com/news/cancer-pat...g-of-genomic-test-results |
||
|
|
Jim Slade
Veteran Cruncher Joined: Apr 27, 2007 Post Count: 664 Status: Offline Project Badges:
|
U.S. agents raid genetic testing labs, charge 35 in Medicare fraud probe
U.S. Federal agents raided genetic testing laboratories, and 35 people were criminally charged in four states in a crackdown on genetic testing fraud that officials said on Friday caused $2.1 billion in losses to federal healthcare insurance programs. http://a.msn.com/01/en-us/AAHWfTA?ocid=se |
||
|
|
l_mckeon
Senior Cruncher Joined: Oct 20, 2007 Post Count: 439 Status: Offline Project Badges:
|
Blood test reveals more than 20 types of cancer
----------------------------------------The latest advance comes from scientists at the Dana-Farber Cancer Institute, who have published a study describing a new type of blood test that can detect more than 20 types of cancer, and even trace them back to their source. The new test was developed by scientists at private company Grail Inc. and was investigated by scientists from Harvard University’s Dana-Farber Cancer Institute. The technology centers on the detection of methyl groups, which are small units of chemicals that can attach themselves to DNA and influence which genes are switched on or off. When these patterns of on-and-off gene expression differ from the norm, they can be indicative of cancer, as we have seen demonstrated through previous studies on cancer-detection blood tests. The newly published study, however, does offer some particularly impressive and wide-ranging results. The researchers applied the sequencing technology that scans for these irregularities to almost 3,600 blood samples, drawn from both healthy subjects and patients suffering from more than 20 types of cancer. It indicated the presence of the cancers with 99.4 percent accuracy, meaning that just 0.6 percent were incorrect diagnoses of healthy subjects. More info at: https://newatlas.com/medical/blood-test-20-types-of-cancer/ [Edit 1 times, last edit by l_mckeon at Oct 1, 2019 2:29:39 AM] |
||
|
|
Jim Slade
Veteran Cruncher Joined: Apr 27, 2007 Post Count: 664 Status: Offline Project Badges:
|
Exploring the Current Landscape of Consumer Genomics - A Workshop/Webinar - 10/29/2019
The Roundtable of Genomics and Precision Health will host a public workshop/webinar on October 29, 2019 to explore the current landscape of consumer genomics for how genetic test information is used or may be used in research and clinical care. Discussions include topics such as health literacy and engagement, knowledge gaps, and data privacy concerns. When: October 29,2019 (8:30 AM Eastern) Where: Keck Center (100) * 500 Fifth St. N.W. Washington, D.C. 20001 Topics: Biomedical and Health Research, Public Health Activity: Roundtable on Genomic and Precision Health Board: Board on Health Science Policy http://www.nationalacademies.org/hmd/Activiti...Research/2019-Oct-29.aspx |
||
|
|
l_mckeon
Senior Cruncher Joined: Oct 20, 2007 Post Count: 439 Status: Offline Project Badges:
|
In the Pancreas, Common Fungi May Drive Cancer
More detailed post in Microbiome link below. https://www.worldcommunitygrid.org/forums/wcg/viewpostinthread?post=615273 |
||
|
|
|